Together, these findings support that integrin-mediated mTOR signaling drives TGF-β overactivation, inflammation, and myxomatous mitral valve degeneration, and we propose mTOR inhibition as a possible medical therapy for MVP. Here, TGFB1 is linked to familial mitral valve prolapse.